EVMN earnings
Evommune Inc. (EVMN) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights- Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV1 molecular glue degrader - EVO301 late-breaking EADV data demonstrate clear therapeutic signal and favorable safety and tolerability profile, supporting Phase 2b trial in AD expected for mid-2027 initiation - Additional clinical milestones expected in 2027, including initiation of the EVO570 Phase 1 trial in early 2027, the EVO301 Phase 2 trial in ulcerative colitis and the EVO646 Phase 1 study - Key 2027 data expected to include Phase 1 healthy volunteer and biomarker data for EVO570 and EVO646, and top-line Phase 2b migraine data for EVO756 - Strong balance sheet with cash runway into 2H 2029 to de
- Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis- Trial met primary efficacy endpoint at week 12 - EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo - 33% placebo-adjusted improvement in EASI at week 12 - 23% of EVO301 patients achieved IGA 0/1 at week 12 - Company to hold conference call and webcast at 8:30 a.m. ET today Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of